For patients with recurrent or metastatic HNSCC, 800 mg/day of the CSF1R-targeted drug Pazopanib oral suspension in combination with standard weekly cetuximab had observed encouraging preliminary anti-tumor activity (Dincer et al. 2019; Adkins et al. 2018). This evidence concerns the gene CSF1R and neoplasm.